<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31807">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943318</url>
  </required_header>
  <id_info>
    <org_study_id>BRM_LC_Cohort</org_study_id>
    <nct_id>NCT01943318</nct_id>
  </id_info>
  <brief_title>Boramae Liver Cirrhosis Cohort Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis represents a worldwide health problem and is a major cause of mortality.
      Cirrhosis is the common end for chronic alcohol abuse and hepatitis C and B virus
      infections. Patients who have cirrhosis have varying degrees of compensated liver function,
      and clinicians need to differentiate between those who have stable, compensated cirrhosis
      and those who have decompensated cirrhosis. It is shown various complications: portal
      hypertension, hepatocellular carcinoma, hepato-renal syndrome, etc.

      Thus, it is important to have this information to manage disease and determine specific
      therapy. However, register-based studies in have not been reported in Korea.

      The goal of this study is to describe the natural history of a large number of patients with
      liver cirrhosis prospectively followed, and to identify predictors of the occurrence of
      Hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are planning to recruit patients with liver cirrhosis, and collect the
      baseline clinical laboratory data. Biological tests, endoscopy,liver ultrasonography
      (including ARFI) and HVPG measurements will be performed if not done within 90 days prior to
      inclusion. During this visit, 20 ml of blood will be collected for freezing and storage of
      serum and plasma, and constitution of a DNA library.

      Monitoring: Patients will have regular surveillance with blood test, liver ultrasonography
      and medical consultation at least every 6 months, periodic assessment of esophageal, gastric
      varices and portal hypertensive gastropathy (every 1 year) and prevention of their rupture
      if any. An additional blood sampling of 20 ml will be taken at baseline and every year in
      order to perform whole blood, serum, plasma, PBMC and DNA libraries; Data will be
      standardized and centralized in a single database.

      And alcoholic LC patients will undergo liver biopsy for PCR, wetern blot,
      immunohistochemistry and RNA analysis.

      After measurement of HVPG and Liver stiffness at baseline a Non-selective beta-blocker
      (NSBB,carvedilol) was initiated and increased stepwise (weekly) until the systolic blood
      pressure remained at&gt;100 mmHg and the heart rate was not &lt;60. The maximum target dose for
      carvedilol 25 mg/day. The HVPG response to NSBB was again assessed 6 weeks after the intake
      of carvedilol. A hemodynamic response to NSBB treatment was defined as a reduction in HVPG
      &gt;=20% compared to baseline or to an absolute value &lt;=12 mmHg. Compliance with therapy was
      monitored by monitoring of HR and blood pressure during clinical visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2018 Years</target_duration>
  <primary_outcome>
    <measure>Liver-related outcome: Decompensated liver cirrhosis, occurance of hepatocellular carcinoma</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative incidence within 5 years Laboratory Tests: Albumin, Total bilirubin, PT, Platelet Hepatic venous pressure gradient measurement Imaging study like Liver CT or Liver ultrasonography Endoscopy for varix evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>overall mortality - whatever the cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver-related mortality</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>cumulative incidence of liver-related deaths</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <description>Alcoholic Liver Cirrhosis
Participants will undergo liver biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <description>HBV Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <description>HCV Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune</arm_group_label>
    <description>Autoimmune Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary</arm_group_label>
    <description>Primary or secondary biliary cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toxic</arm_group_label>
    <description>Medication related cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Others</arm_group_label>
    <description>Other cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <arm_group_label>Hepatitis C virus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG measurement</intervention_name>
    <description>paired measurement</description>
    <arm_group_label>Alcohol</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At enrollement, 20 ml of blood will be collected for freezing and storage of serum and
      plasma, and constitution of a DNA library
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Seoul National University Boramae hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥19years old Proven cirrhosis

          -  No previous HCC (treated or not)

          -  Signed informed consent

        Exclusion Criteria:

          -  serious associated short-term life threatening disease (except associated HIV viral
             infection and the liver disease itself)

          -  liver focal lesion suggestive of HCC

          -  patient under guardianship

          -  pregnant women

          -  inability to regular monitoring, for whatever reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hwi Young Kim, MD,PhD</last_name>
    <phone>821032411321</phone>
    <email>hykim@brmh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>SNU-SMG Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hwi Young Kim, MD.PhD.</last_name>
      <phone>821032411321</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012 Jun;47(6):702-9. doi: 10.3109/00365521.2012.661759. Epub 2012 Mar 19.</citation>
    <PMID>22428859</PMID>
  </reference>
  <reference>
    <citation>Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012 May;47(5):561-8. doi: 10.1007/s00535-011-0517-4. Epub 2011 Dec 15.</citation>
    <PMID>22170417</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Hwi Young Kim, MD.PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
